Soomro S, Shousha S, Taylor P, Shepard H M, Feldmann M
Department of Histopathology, Charing Cross and Westminster Medical School, London.
J Clin Pathol. 1991 Mar;44(3):211-4. doi: 10.1136/jcp.44.3.211.
Sections of 149 breast carcinomas were examined for the over-expression of c-erbB-2 oncoprotein using the avidin-biotin immunoperoxidase technique and two different specific antibodies. These included the polyclonal antibody 21N and the monoclonal antibody 4D5. The tumours were divided into two main groups. The first included 75 cases of invasive ductal and classic invasive lobular carcinomas. The second group consisted of 74 cases with histological types known to have a good prognosis, including mucinous, alveolar variant of invasive lobular, medullary, tubular, cribriform and papillary carcinomas. Fifteen (20%) tumours of the first group were positive with the two antibodies. Fourteen of these were of the ductal type and one was a mixed invasive ductal and lobular carcinoma. Ten of the pure ductal cases had areas of comedo carcinoma. The intraductal elements in a further tumour were positively stained with 21N antibody only. None of the second group of tumours, which included histological types known to have good prognosis, stained with 4D5, although one mucinous carcinoma was positively stained with 21N. These findings suggest that in invasive breast carcinoma immunostaining for c-erbB-2 is mainly seen in a subgroup of ductal tumours, and that almost all other histological types, especially those associated with good prognosis, lack this expression.
采用抗生物素蛋白-生物素免疫过氧化物酶技术和两种不同的特异性抗体,对149例乳腺癌组织切片进行c-erbB-2癌蛋白过表达检测。这两种抗体包括多克隆抗体21N和单克隆抗体4D5。肿瘤被分为两个主要组。第一组包括75例浸润性导管癌和经典浸润性小叶癌。第二组由74例已知预后良好的组织学类型肿瘤组成,包括黏液癌、浸润性小叶癌的肺泡样变型、髓样癌、管状癌、筛状癌和乳头状癌。第一组中有15例(20%)肿瘤两种抗体检测均为阳性。其中14例为导管型,1例为浸润性导管癌和小叶癌混合型。10例单纯导管型病例中有粉刺癌区域。另一例肿瘤的导管内成分仅用21N抗体呈阳性染色。第二组肿瘤包括已知预后良好的组织学类型,均无4D5染色阳性,但有1例黏液癌21N染色阳性。这些发现提示,在浸润性乳腺癌中,c-erbB-2免疫染色主要见于导管肿瘤亚组,几乎所有其他组织学类型,尤其是那些预后良好的类型,均缺乏这种表达。